Doxazosin (Mesylate)

Doxazosin should be used with caution in patients with hepatic disease (the drug is primarily metabolized by the liver) and administration of noral doses of drug may results in exaggerated effects in these patients. Patients with renal impairment should be monitored carefully for exaggerated effects, such as first-dose hypotensive reaction or prolonged hypotension. It is classified as FDA pregnancy category B. This medication should be used only when clearly needed during pregnancy or lactation. Blood pressure should be monitored for 2-6 hours following the first dose and with each subsequent increase in dose because postural hypotensive effects are most likely to occur during this time. Dosages should be adjusted as necessary depending on patient tolerance as evidenced by standing blood pressure. It should not be administered to any patient who has hypotension. Elderly patients are more likely to be susceptible to hypotensive effects.